Empowering Hope: Salvia BioElectronics Secures $60M Series B to Revolutionize Migraine & Neurological Care

Salvia BioElectronics is thrilled to announce that it has successfully raised $60,000,000 in new funding, marking a significant milestone in our journey to transform migraine treatment and advance neurological healthcare. As a pioneer in the field of medical devices, our mission is dedicated to giving people with migraine a better life by empowering them to reclaim their days and restore joy and vitality. This impressive infusion of capital will not only accelerate the development of our personalized migraine therapy—designed to meet the distinctive needs of each patient—but will also fuel our innovative research into broader applications of bioelectronic technology for other neurological disorders. Our state-of-the-art approach harnesses cutting-edge bioelectronic technology, setting us apart from traditional treatment methods. This funding is a testament to the trust our investors place in our ability to make a profound impact on patient care. With these resources, Salvia BioElectronics plans to expand its clinical trials, enhance product development, and solidify strategic collaborations with leading global healthcare institutions. Moreover, the funds will support further advancements in our technology platform, ensuring that our therapeutic solutions remain at the forefront of medical innovation. Comprised of experienced entrepreneurs, engineers, scientists, and industry veterans from renowned organizations like Sapiens, Medtronic, Philips, St Jude, and BioSensors International, our diverse team is uniquely positioned to drive these transformative initiatives. Our vision extends beyond simply managing migraine symptoms—we aim to herald a new era of hope, health, and happiness for individuals and their families worldwide. This funding announcement is not just a financial milestone, but a powerful affirmation of our commitment to improving the quality of life for millions of people suffering from neurological challenges.